Viridian Therapeutics (UK) Today
| 0K1R Stock | 11.99 0.24 1.96% |
Performance0 of 100
| Odds Of DistressOver 68
|
Viridian Therapeutics is selling for under 11.99 as of the 6th of July 2024; that is 1.96% down since the beginning of the trading day. The stock's lowest day price was 11.99. Viridian Therapeutics has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Viridian Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of May 2024 and ending today, the 6th of July 2024. Click here to learn more.
Business Domain Commercial & Professional Services | Classification Industrials |
Viridian Therapeutics is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 30.84 M outstanding shares. More on Viridian Therapeutics
Moving against Viridian Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Viridian Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Viridian Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Viridian Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | MBA JD | ||||
| Business Concentration | Environmental & Facilities Services, Commercial & Professional Services, Industrials, Industrials, Commercial Services & Supplies, Commercial & Professional Services, Industrials (View all Sectors) | ||||
Viridian Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Viridian Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Viridian Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Viridian Therapeutics' financial leverage. It provides some insight into what part of Viridian Therapeutics' total assets is financed by creditors.
| |||||
Viridian Therapeutics (0K1R) is traded on London Exchange in UK and employs 94 people. Viridian Therapeutics is listed under Environmental & Facilities Services category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 2.84 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Viridian Therapeutics's market, we take the total number of its shares issued and multiply it by Viridian Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Viridian Therapeutics operates under Commercial Services & Supplies sector and is part of Industrials industry. The entity has 30.84 M outstanding shares.
Viridian Therapeutics generates negative cash flow from operations
Check Viridian Therapeutics Probability Of Bankruptcy
Ownership AllocationViridian Therapeutics maintains a total of 30.84 Million outstanding shares. The majority of Viridian Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Viridian Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Viridian Therapeutics. Please pay attention to any change in the institutional holdings of Viridian Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Viridian Ownership Details
Viridian Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Viridian Therapeutics market risk premium is the additional return an investor will receive from holding Viridian Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Viridian Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Viridian Therapeutics' alpha and beta are two of the key measurements used to evaluate Viridian Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.82 | |||
| Standard Deviation | 3.62 | |||
| Variance | 13.11 | |||
| Risk Adjusted Performance | (0.06) |
Viridian Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Viridian Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Viridian Therapeutics Corporate Management
Elected by the shareholders, the Viridian Therapeutics' board of directors comprises two types of representatives: Viridian Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viridian. The board's role is to monitor Viridian Therapeutics' management team and ensure that shareholders' interests are well served. Viridian Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viridian Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA | Chief Officer | Profile | |
| Seth Harmon | Principal Accounting | Profile | |
| Anthony Casicano | Chief Officer | Profile | |
| John Jordan | Vice Communications | Profile | |
| Anthony Casciano | Chief Officer | Profile |
Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.